川黄方治疗3~4期CKD患者的临床疗效及对尿IL⁃18、γ⁃GT的影响
Clinical efficacy of Chuanhuang Formula in treating patients with chronic kidney disease at stages 3⁃4 and its influence on urinary IL⁃18 and γ⁃GT
- 上海中医药大学学报 2023年37卷第2期 页码：48-53
- 作者机构：
1.上海中医药大学附属市中医医院肾病科（上海 200071）
- 作者简介：
王丹军，男，硕士，住院医师，主要从事中医药防治急慢性肾病的临床与基础研究
龚学忠，教授、主任医师，博士生导师；E-mail： shnanshan@yeah.net
- 基金信息：国家自然科学基金面上项目(82074387;81873280);上海市科委医学创新研究专项项目(20Y21902200)
DOI：10.16306/j.1008-861x.2023.02.008
中图分类号：
扫 描 看 全 文
王丹军,龚学忠.川黄方治疗3~4期CKD患者的临床疗效及对尿IL⁃18、γ⁃GT的影响[J].上海中医药大学学报,2023,37(02):48-53.
WANG Danjun,GONG Xuezhong.Clinical efficacy of Chuanhuang Formula in treating patients with chronic kidney disease at stages 3⁃4 and its influence on urinary IL⁃18 and γ⁃GT[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2023,37(02):48-53.
王丹军,龚学忠.川黄方治疗3~4期CKD患者的临床疗效及对尿IL⁃18、γ⁃GT的影响[J].上海中医药大学学报,2023,37(02):48-53. DOI： 10.16306/j.1008-861x.2023.02.008.
WANG Danjun,GONG Xuezhong.Clinical efficacy of Chuanhuang Formula in treating patients with chronic kidney disease at stages 3⁃4 and its influence on urinary IL⁃18 and γ⁃GT[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2023,37(02):48-53. DOI： 10.16306/j.1008-861x.2023.02.008.
摘要
目的,2,观察川黄方治疗3~4期慢性肾脏病（CKD）患者的临床疗效，并探讨其对患者尿液中白介素-18（IL-18）、γ-谷氨酰转移酶（γ-GT）水平的影响。,方法,2,将符合标准的70例3~4期CKD患者按照1∶1比例随机分为治疗组和对照组，每组各35例。对照组患者给予西医常规药物治疗，治疗组患者在对照组治疗基础上联合川黄方口服，疗程为12周。评估两组患者的临床疗效；治疗前后评价并比较两组患者的中医证候总积分；检测所有患者的肾功能指标［包括血清肌酐（Scr）、尿素氮（BUN）、尿酸（UA）、估算肾小球滤过率（eGFR）］、急性肾损伤（AKI）标志物（包括尿IL-18、 γ-GT）水平及24 h 尿蛋白定量（24 h U-Pro）。,结果,2,①治疗后，治疗组患者的临床总有效率为68.6%，对照组为42.9%，治疗组的疗效优于对照组（,P,<,0.01）。②治疗后，两组患者的中医证候总积分较治疗前均显著降低（,P,<,0.01），且治疗组患者的积分低于对照组（,P,<,0.05）。③治疗后，两组患者的eGFR水平较治疗前升高（,P,˂0.01），Scr、BUN水平较治疗前降低（,P,˂0.01），且治疗组患者的eGFR水平高于对照组（,P,˂0.05），Scr、BUN水平低于对照组（,P,˂0.05）。④治疗后，治疗组患者的24 h U-Pro水平较治疗前明显降低（,P,<,0.01），且低于对照组（,P,<,0.05）；而对照组患者的24 h U-Pro水平治疗前后比较差异无统计学意义（,P,>,0.05）。⑤治疗后，治疗组患者的尿IL-18、γ-GT水平较治疗前均降低（,P,<,0.01），对照组患者的尿IL-18水平较治疗前亦降低（,P,<,0.01），且治疗组患者的尿IL-18、γ-GT水平低于对照组（,P,<,0.05）。,结论,2,与单纯西医常规治疗比较，川黄方结合西医常规治疗能更好地保护3~4期CKD患者的肾功能，促进肾功能恢复，改善患者的中医证候，并能降低患者的尿IL-18、γ-GT水平。
Abstract
Objective： To observe the clinical efficacy of Chuanhuang Formula in treating patients with chronic kidney disease （CKD） at stages 3-4， and explore its influence on the levels of urinary interleukin-18 （IL-18） and γ-glutamyl transferase （γ-GT）.,Methods,2,A total of 70 patients with CKD at stages 3-4 who met the criteria were randomly divided into the treatment group and control group according to 1∶1 ratio， 35 cases in each group. The patients in the control group were treated with conventional western medicine. The patients in the treatment group were treated with Chuanhuang Formula orally based on the treatment of the control group. The treatment course was 12 weeks. The clinical efficacy of the two groups was evaluated. The total scores of Chinese medical syndrome in the two groups were evaluated and compared before and after treatment. The levels of renal function indexes ［including serum creatinine （Scr）， blood urea nitrogen （BUN）， uric acid （UA） and estimated glomerular filtration rate （eGFR）］， acute kidney injury （AKI） markers （including urinary IL-18 and γ-GT） and 24-hour urinary protein quantification （24 h U-Pro） were detected.,Results,2,①After treatment， the total clinical effective rate was 68.5% in the treatment group and 42.8% in the control group， and the effect of the treatment group was better than that of the control group （,P,˂0.01）. ②After treatment， the total scores of Chinese medical syndrome in the two groups were significantly decreased compared with those before treatment （,P,<,0.01）， and the score of the treatment group was lower than that of the control group （,P,<,0.05）. ③After treatment， the level of eGFR in the two groups was increased compared with that before treatment （,P,˂0.01）， the levels of Scr and BUN were decreased compared with those before treatment （,P,˂0.01）， and the level of eGFR in the treatment group was higher than that in the control group （,P,˂0.05）， the levels of Scr and BUN were lower than those in the control group （,P,˂0.05）. ④After treatment， the level of 24 h U-Pro in the treatment group was significantly decreased compared with that before treatment （,P,<,0.01）， and was lower than that in the control group （,P,<,0.05）， while there was no statistically significant difference on the level of 24 h U-Pro in the control group between before and after treatment （,P,>,0.05）. ⑤After treatment， the levels of urinary IL-18 and γ-GT in the treatment group were decreased compared with those before treatment （,P,<,0.01）， the level of urinary IL-18 in the control group was also decreased compared with that before treatment （,P,<,0.01）， and the levels of urinary IL-18 and γ-GT in the treatment group were lower than those in the control group （,P,<,0.05）.,Conclusion,2,Compared with conventional western medicine only， Chuanhuang Formula combined with conventional western medicine could better protect the renal function， promote the recovery of the renal function， improve the Chinese medical syndrome， and reduce the levels of urinary IL-18 and γ-GT in patients with CKD at stages 3-4.
关键词
慢性肾脏病川黄方白介素-18γ-谷氨酰转移酶急性肾损伤标志物
Keywords
chronic kidney diseaseChuanhuang Formulainterleukin-18γ-glutamyl transferasemarkers of acute kidney injury
references
LV J C， ZHANG L X. Prevalence and disease burden of chronic kidney disease［J］. Adv Exp Med Biol， 2019， 1165： 3-15.
ZHAO M， YU Y， WANG R， et al. Mechanisms and efficacy of Chinese herbal medicines in chronic kidney disease［J］. Front Pharmacol， 2021， 11： 619201.
郑平东. 慢性肾衰竭病因病机与临证辨治［J］. 上海中医药大学学报， 2008， 22（2）： 1-3.
ZHENG P D. Etiology， Pathogenesis， Syndrome Differentiation and Treatment of Chronic Renal Failure［J］. Journal of Shanghai University of Traditional Chinese Medicine， 2008， 22（2）： 1-3.
龚学忠， 周令芳， 王骞， 等. 川黄1号方对慢性肾脏病3期患者肾功能及微炎症状态的影响［J］. 中国中西医结合杂志， 2015， 35（2）： 137-141.
GONG X Z， ZHOU L F， WANG Q， et al. Effect of Chuanhuang No. 1 Recipe on Renal Function and Micro-inflammation in Phase 3 Chronic Kidney Disease Patients［J］. Chinese Journal of Integrated Traditional and Western Medicine， 2015， 35（2）： 137-141.
龚学忠， 叶紫， 徐向南， 等. 川黄方联合前列腺素E1方案治疗慢性肾脏病合并急性肾损伤的疗效及对患者NLRP3的影响［J］. 上海中医药大学学报， 2021， 35（6）： 12-16.
GONG X Z， YE Z， XU X N， et al. Effects of Chuanhuang Formula combined with prostaglandin E1 in treating patients of chronic kidney disease complicated with acute kidney injury and its influence on NLRP3［J］. Journal of Shanghai University of Traditional Chinese Medicine， 2021， 35（6）： 12-16.
龚学忠， 汤晓春， 王骞， 等. 川黄方联合前列腺素E1对60例2~4期CKD合并AKI患者的疗效观察［J］. 中国中西医结合肾病杂志， 2014（9）： 784-787.
GONG X Z， TANG X C， WANG Q， et al. Observe the Clinical Efficacy of Chuanhuang Decoction Combined with Lipo PGE1 in Treating Acute Kidney Injury （AKI） on Phase 2~4 Chronic Kidney Disease （CKD） Patients［J］. Chinese Journal of Integrated Traditional and Western Nephrology， 2014（9）： 784-787.
CHEN L， GONG X Z. Efficacy and Safety of Chuan Huang Fang Combining Reduced Glutathione in Treating Acute Kidney Injury （Grades 1-2） on Chronic Kidney Disease （Stages 2-4）： Study Protocol for a Multicenter Randomized Controlled Clinical Trial［J］. Evid Based Complement Alternat Med， 2022， 2022： 1099642.
PENG S， LIU N， WEI K， et al. The Predicted Value of Kidney Injury Molecule-1 （KIM-1） in Healthy People［J］. Int J Gen Med， 2022， 15： 4495-4503.
徐欢， 龚学忠. 急性肾损伤标志物在慢性肾脏病中的意义及中医治疗［J］. 中华中医药学刊， 2016， 34（2）： 323-325.
XU H， GONG X Z. Significance of Biological Markers of Acute Kidney Injury and TCM Treatment［J］.Chinese Archives of Traditional Chinese Medicine， 2016， 34（2）： 323-325.
THOMAS J M， HUUSKES B M， SOBEY C G， et al. The IL-18/IL-18R1 signalling axis： Diagnostic and therapeutic potential in hypertension and chronic kidney disease［J］. Pharmacol Ther， 2022， 239： 108191.
龚学忠， 徐欢， 王骞， 等. 川黄1号方对慢性肾脏病3期患者尿IL-18及 Kim-1的影响［J］. 上海中医药大学学报， 2016， 30（6）： 14-18.
GONG X Z， XU H， WANG Q， et al. Influence of “Chuanhuang Recipe No.1” on Urinary IL-18 and Kim-1 in Patients with Chronic Kidney Disease at Phase 3［J］. Journal of Shanghai University of Traditional Chinese Medicine， 2016， 30（6）： 14-18.
Kidney Disease： Improving Global Outcomes （KDIGO） Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases［J］. Kidney Int， 2021， 100（4S）： S1-S276.
郑筱萸. 中药新药临床研究指导原则（试行）［M］. 北京： 中国医药科技出版社， 2002： 156-161.
ZHENG X Y. Guiding Principles for Clinical Research of New Drugs of Traditional Chinese Medicine （trial implementation）［M］. Beijing： China Medical Science Press， 2002： 156-161.
中华中医药学会肾病分会. 慢性肾衰竭的诊断、辨证分型及疗效评定（试行方案）［J］. 上海中医药杂志， 2006， 40（8）： 8-9.
Kidney Disease Branch of Chinese Society of Traditional Chinese Medicine. Diagnosis， syndrome differentiation and curative effect evaluation of chronic renal failure （trial plan） ［J］. Shanghai Journal of Traditional Chinese Medicine， 2006， 40（8）： 8-9.
沈蓉， 卢锦花. 慢性肾功能衰竭的中医辨证治疗［J］. 中华现代中西医结合， 2005， 2（12）： 11-12.
SHEN R， LU J H. TCM Syndrome Differentiation and Treatment of Chronic Renal Failure［J］. Chinese Medicine and Western Medicine Integrating， 2005， 2（12）： 11-12.
龚学忠， 郑君丽， 段怡汝， 等. 川黄方对临床剂量三价砷肾毒性大鼠肾小管上皮细胞凋亡的影响［J］. 北京医学， 2019， 41（12）： 1089-1093.
GONG X Z， ZHENG J L， DUAN Y R， et al. Effect of Chuanhuang Fang on apoptosis of renal tubular epithelial cells in rats with trivalent arsenic nephrotoxicity［J］. Beijing Medical Journal， 2019， 41（12）： 1089-1093.
龚学忠， 邱安东，段怡汝，等. 制大黄-川芎药对对CIN 大鼠肾组织Nrf2 /HO-1 信号通路的影响［J］. 上海中医药大学学报， 2017， 31（6）： 58-61.
GONG X Z， QIU A D， DUAN Y R， et al. Effects of Couplet Medicines of Prepared Radix et Rhizoma Rhei-Rhizoma Ligustici Chuanxiong on Nrf2/HO-1 Signaling Pathway in Renal Tissue of Contrast-induced Nephropathy Rats［J］. Journal of Shanghai University of Traditional Chinese Medicine， 2017， 31（6）： 58-61.
王海霞， 牟洪宾， 於江泉， 等. NGAL、KIM-1、TIMP-2对脓毒症所致AKI早期诊断价值的前瞻性临床队列研究［J］. 中华重症医学电子杂志， 2019， 5（2）： 120-126.
WANG H X， MOU H B， YU J Q， et al. Evaluation of NGAL， KIM-1， and TIMP-2 as early biomarkers in sepsis-associated acute kidney injury： a prospective clinical cohort study［J］. Chinese Journal of Critical Care & Intensive Care Medicine， 2019， 5（2）： 120-126.
MENEZ S， PARIKH C R. Assessing the health of the nephron in acute kidney injury： biomarkers of kidney function and injury［J］. Curr Opin Nephrol Hypertens， 2019， 28（6）： 560-566.
黄宏耀， 朱波， 王翠， 等. 尿 γ-GT， β2-MG， 尿微量白蛋白联合检测对高血压和糖尿病患者早期肾损伤的诊断意义［J］. 微循环学杂志， 2006， 16（3）： 81， 83.
HUANG H Y， ZHU B， WANG C， et al. Diagnostic significance of combined detection of urinary γ-GT， β2-MG and urinary microalbumin in early renal injury in patients with hypertension and diabetes［J］. Chinese Journal of Microcirculation， 2006， 16（3）： 81， 83.
SHANG W， WANG Z. The update of NGAL in Acute Kidney Injury［J］. Curr Protein Pept Sci， 2017， 18（12）： 1211-1217.
0
浏览量
107
下载量
0
CSCD
0
CNKI被引量
- 网络PDF下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
- 总访问量：10154 今日访问量：17